# A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)

> **NCT07645248** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 110 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** HFA-152a
- **DRUG:** HFA-134a

## Key facts

- **NCT ID:** NCT07645248
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-02-25
- **Final completion:** 2027-02-25
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07645248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07645248, "A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07645248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*